Malnourished adolescents with AN requiring medical hospitalization are at high risk for rapid reduction in skeletal quality. Even short-term bed rest can suppress normal patterns of bone turnover. We sought to determine whether LMMS normalizes bone turnover among adolescents hospitalized for complications of AN. In this randomized, double-blind trial, we prospectively enrolled adolescent females (n=41) with AN, age 16.3±1.9years (mean±SD) and BMI 15.6±1.7kg/m2. Participants were randomized to stand on a platform delivering LMMS (0.3g at 32-37Hz) or placebo platform for 10min/day for 5days. Serum markers of bone formation [bone-specific alkaline phosphatase (BSAP)], turnover [osteocalcin (OC)], and bone resorption [serum C-telopeptides (CTx)] were measured. From a random coefficients model, we constructed estimates and confidence intervals for all outcomes. BSAP decreased by 2.8% per day in the placebo arm (p=0.03) but remained stable in the LMMS group (p=0.51, pdiff=0.04). CTx did not change with placebo (p=0.56) but increased in the LMMS arm (+6.2% per day, p=0.04; pdiff=0.01). Serum OC did not change in either group (p>0.70). Bed rest during hospitalization for patients with AN is associated with a suppression of bone turnover, which may contribute to diminished bone quality. Brief, daily LMMS prevents a decline in bone turnover during bed rest in AN. Protocols prescribing strict bed rest may not be appropriate for protecting bone health for these patients. LMMS may have application for these patients in the inpatient setting.